Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT3 | Q9Y243 | 5/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.36 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | HTR5A | P47898 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990318 | 0.92 | AKT3 (0.42) | AKT3CDK2CLK1EIF2AK2MAPK3 | |
| SCHEMBL2975816 | 0.88 | MAPK3 (0.38) | AKT3CDK2CLK1EIF2AK2MAPK3 | |
| SCHEMBL5147497 | 0.86 | AKT3 (0.41) | AKT3CDK2CLK1EIF2AK2MAPK1 | |
| SCHEMBL2974881 | 0.84 | MAPK3 (0.39) | AKT3CDK2CLK1EIF2AK2MAPK3 | |
| SCHEMBL2975976 | 0.84 | DKK1 (0.41) | AKT3CDK2CLK1EIF2AK2MAPK3 | |
| SCHEMBL2985174 | 0.84 | USP2 (0.32) | MAPK1 | |
| SCHEMBL2972089 | 0.83 | AKT3 (0.35) | AKT3CDK2CLK1EIF2AK2MAPK3 | |
| SCHEMBL2977020 | 0.83 | AKT3 (0.35) | AKT3CDK2CLK1EIF2AK2MAPK3 | |
| SCHEMBL2977023 | 0.83 | AKT3 (0.35) | AKT3CDK2CLK1EIF2AK2MAPK3 | |
| SCHEMBL2982348 | 0.82 | MEN1 (0.38) | AKT3CDK2CLK1EIF2AK2MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831207-B1 | AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | claimed |
| US-7786132-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-08-31 | — | — | US | claimed |
| EP-1831207-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-09-12 | — | — | EP | claimed |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | AMGEN, INC. (US) | 2007-08-09 | — | — | US | claimed |
| WO-2006066172-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-06-22 | — | — | WO | claimed |
| EP-1831207-B1 | AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-7858785-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7786132-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-1831207-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | AMGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2006066172-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PLK1, TYMP, TK2 | AKT3 920/4885CDK2 23/4885CLK1 363/4885 |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | PLK1, TYMP, TK2 | AKT3 920/4885CDK2 23/4885CLK1 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.